Bevacizumab-Related Gastrointestinal Perforation in Hepatocellular Carcinoma Patient: A Case Report
<p>Introduction: Atezolizumab plus bevacizumab is widely recognized as the first-line treatment for advanced hepatocellular carcinoma (HCC). Bevacizumab, an anti-vascular endothelial growth factor (anti-VEGF), is effective against various cancers but carries a rare risk of gastrointestina...
Na minha lista:
| Principais autores: | , , , |
|---|---|
| 格式: | Artigo |
| 语言: | Inglês |
| 出版: |
Karger Publishers
2025-12-01
|
| 丛编: | Case Reports in Oncology |
| 在线阅读: | https://karger.com/article/doi/10.1159/000549176 |
| 标签: |
没有标签, 成为第一个标记此记录!
|